1. Home
  2. ADAP
  3. ADAP News

Latest Adaptimmune Therapeutics plc (ADAP) News on March 31, 2025

ADAP

Zacks Small Cap Research

6 days ago

ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story

Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
ADAP

GuruFocus.com

9 days ago

Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result

Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
ADAP

GuruFocus.com

10 days ago

Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...

ADAP

Zacks Small Cap Research

11 days ago

ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options

Adaptimmune Provides Q4 and Full Year 2024 Business Update
ADAP

Newsfile

11 days ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
ADAP

FastCompany

13 days ago

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
ADAP

Newsfile

18 days ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds
ADAP

Simply Wall St.

a month ago

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
ADAP

Newsfile

2 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago
ADAP

Simply Wall St.

2 months ago

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
ADAP

Newsfile

3 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

ADAP

MT Newswires

3 months ago

Adaptimmune Therapeutics Chief Financial Officer Gavin Wood to Resign in May 2025

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
ADAP

Newsfile

3 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
ADAP

Newsfile

4 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

ADAP

MT Newswires

4 months ago

Mizuho Cuts Price Target on Adaptimmune Therapeutics to $1.50 From $3, Keeps Outperform Rating

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
ADAP

Simply Wall St.

4 months ago

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Halozyme bids for Evotec; BeiGene gets a new name
ADAP

BioPharma Dive

4 months ago

Halozyme bids for Evotec; BeiGene gets a new name

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
ADAP

Pharmaceutical Technology

5 months ago

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints

ADAP

Zacks Small Cap Research

5 months ago

ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...
ADAP

GuruFocus.com

5 months ago

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...

Adaptimmune Reports Q3 2024 Financial and Business Updates
ADAP

Newsfile

5 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
ADAP

Newsfile

5 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December
ADAP

Newsfile

5 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
ADAP

Newsfile

5 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

ADAP

Zacks Small Cap Research

6 months ago

OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions
ADAP

Simply Wall St.

6 months ago

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
ADAP

GlobeNewswire

6 months ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for September 19th
ADAP

GlobeNewswire

6 months ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Adaptimmune to Participate in Two Bank Conferences this September
ADAP

Newsfile

7 months ago

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago
ADAP

Simply Wall St.

8 months ago

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago

ADAP

Zacks Small Cap Research

8 months ago

ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload

Adaptimmune Reports Q2 2024 Financial and Business Updates
ADAP

Newsfile

8 months ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
ADAP

Pharmaceutical Technology

8 months ago

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

ADAP

Newsfile

8 months ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
ADAP

Pharmaceutical Technology

8 months ago

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

ADAP

MT Newswires

8 months ago

Agilent Technologies' MAGE-A4 Test Approved by FDA for Use With T-Cell Receptor Therapy

ADAP

MT Newswires

8 months ago

Sector Update: Health Care Stocks Decline Premarket Friday

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
ADAP

Benzinga

8 months ago

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
ADAP

BioPharma Dive

8 months ago

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer

ADAP

MT Newswires

8 months ago

Adaptimmune Therapeutics Gets Accelerated Approval of Tecelra From FDA

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
ADAP

Business Wire

8 months ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

ADAP

MT Newswires

8 months ago

HC Wainwright Starts Adaptimmune Therapeutics With Buy Rating, $4 Price Target

Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?
ADAP

Insider Monkey

8 months ago

Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?

5 FDA decisions to watch in the third quarter
ADAP

BioPharma Dive

9 months ago

5 FDA decisions to watch in the third quarter

ADAP

Zacks Small Cap Research

9 months ago

Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
ADAP

Zacks Small Cap Research

10 months ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
ADAP

Yahoo Finance Video

10 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

ADAP

GlobeNewswire

10 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
ADAP

Reuters

10 months ago

California seeks company profits in Big Oil climate lawsuit

ADAP

USA TODAY

10 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
ADAP

GlobeNewswire

10 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
ADAP

Business Wire

10 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
ADAP

Business Wire

10 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
ADAP

GlobeNewswire

10 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Lotto 6/49 - $64 million up for grabs in the next draw!
ADAP

CNW Group

10 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
ADAP

Simply Wall St.

10 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
ADAP

AFP

10 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
ADAP

Simply Wall St.

10 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
ADAP

Simply Wall St.

10 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
ADAP

Barrons.com

10 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
ADAP

Simply Wall St.

10 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
ADAP

Simply Wall St.

10 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP

Newsfile

10 months ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

ADAP

MT Newswires

10 months ago

Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP

Newsfile

10 months ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

ADAP

MT Newswires

10 months ago

Scotiabank Starts Adaptimmune Therapeutics With Sector Outperform Rating

ADAP

MT Newswires

10 months ago

Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating

ADAP

MT Newswires

10 months ago

Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital

Adaptimmune Reports Q1 2024 Financial and Business Updates
ADAP

Newsfile

a year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
ADAP

Newsfile

a year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
ADAP

Newsfile

a year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune (ADAP) Down on End of Collaboration With Roche
ADAP

Zacks

a year ago

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
ADAP

Newsfile

a year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Roche, Adaptimmune part ways on cell therapy research
ADAP

BioPharma Dive

a year ago

Roche, Adaptimmune part ways on cell therapy research

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
ADAP

Newsfile

a year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
ADAP

Simply Wall St.

a year ago

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
ADAP

GuruFocus.com

a year ago

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
ADAP

Insider Monkey

a year ago

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
ADAP

Newsfile

a year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
ADAP

Newsfile

a year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
ADAP

Newsfile

a year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

15 Top Performing European Stocks So Far in 2024
ADAP

Insider Monkey

a year ago

15 Top Performing European Stocks So Far in 2024

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP

Zacks

a year ago

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
ADAP

Newsfile

a year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC
ADAP

GuruFocus.com

a year ago

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

With 30% stake, 1stdibs.Com, Inc. (NASDAQ:DIBS) seems to have captured institutional investors' interest
ADAP

Simply Wall St.

a year ago

With 30% stake, 1stdibs.Com, Inc. (NASDAQ:DIBS) seems to have captured institutional investors' interest

First Mid Bancshares Full Year 2023 Earnings: EPS Misses Expectations
ADAP

Simply Wall St.

a year ago

First Mid Bancshares Full Year 2023 Earnings: EPS Misses Expectations

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript
ADAP

Insider Monkey

a year ago

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago
ADAP

Simply Wall St.

a year ago

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

Why WW International Stock Bounced 6% Higher Today
ADAP

Motley Fool

a year ago

Why WW International Stock Bounced 6% Higher Today

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024
ADAP

PR Newswire

a year ago

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

Dakota Gold Intersects Multiple High-Grade Zones with Visible Gold Mineralization, Including 4.871 oz/ton Au over 3.4 ft (167.0 g/t over 1.0 m), 1200 feet South of the JB Gold Zone on Its Maitland Gold Project
ADAP

Newsfile

a year ago

Dakota Gold Intersects Multiple High-Grade Zones with Visible Gold Mineralization, Including 4.871 oz/ton Au over 3.4 ft (167.0 g/t over 1.0 m), 1200 feet South of the JB Gold Zone on Its Maitland Gold Project

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
ADAP

Simply Wall St.

a year ago

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
ADAP

Zacks

a year ago

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Insider Sell: Solid Power Inc CTO Joshua Buettner-garrett Sells 187,500 Shares
ADAP

GuruFocus.com

a year ago

Insider Sell: Solid Power Inc CTO Joshua Buettner-garrett Sells 187,500 Shares

Smartfren Telecom and Aviat Establish Strategic Collaboration in Indonesia
ADAP

PR Newswire

a year ago

Smartfren Telecom and Aviat Establish Strategic Collaboration in Indonesia

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
ADAP

PR Newswire

a year ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

The Zacks Analyst Blog Highlights VirTra, REX American Resources, Universal Stainless & Alloy Products, Runway Growth Finance and Carrols Restaurant Group
ADAP

Zacks

a year ago

The Zacks Analyst Blog Highlights VirTra, REX American Resources, Universal Stainless & Alloy Products, Runway Growth Finance and Carrols Restaurant Group

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
ADAP

Newsfile

a year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Camden National Corporation to Announce Quarter and Year Ended December 31, 2023 Financial Results on January 30, 2024
ADAP

PR Newswire

a year ago

Camden National Corporation to Announce Quarter and Year Ended December 31, 2023 Financial Results on January 30, 2024

Share on Social Networks: